Rendering

Component: (Network and Table)
Network
2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)
(http://www.cbiolabs.com/role/SummaryOfSignificantAccountingPoliciesTables)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0001318641 (http://www.sec.gov/CIK)
Accounting Policies [Abstract]Period [Axis]
2016-01-01 - 2016-12-31
Accounting Policies [Abstract]
 
Revenue by Customer
The following table presents our revenue by customer, on a proportional basis, for the periods indicated:
 
Years ended December 31,
 
 
 
2016
 
2015
 
Variance
U.S. Department of Defense
35.4
%
 
7.9
%
 
27.5
 %
Russian government agencies
46.9
%
 
59.6
%
 
(12.7
)%
Incuron, LLC
17.7
%
 
32.5
%
 
(14.8
)%

100.0
%
 
100.0
%
 
—
 %
  
Property, Plant, and Equipment Useful Lives
Equipment is depreciated using the straight-line method over the estimated useful lives of the respective assets as follows:
 
        
Asset Category
Estimated Useful Life
(in Years)
Laboratory equipment
5
Furniture and fixtures
5
Computer equipment
3
  
Changes in Accumulated Other Comprehensive Income (Loss)
The following table presents the changes in accumulated other comprehensive loss for the year ended December 31, 2016.
 
Unrealized loss on available-for-sale securities
 
Gains and losses on foreign exchange translations
 
Total
Beginning balance
$
(6,190
)
 
$
(401,861
)
 
$
(408,051
)
Other comprehensive income/(loss) before reclassifications
3,904

 
(158,537
)
 
(154,633
)
Amounts reclassified from accumulated other comprehensive loss
—

 
(1,875
)
 
(1,875
)
Ending balance
$
(2,286
)
 
$
(562,273
)
 
$
(564,559
)
  
Summary of Assumptions Used in Valuing Stock Options Granted
The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. No options were granted during the year ended December 31, 2016. Set forth below are the assumptions used in valuing the stock options granted and a discussion of the Company’s methodology for developing each of the assumptions used:
        
 
 
2015
Risk-free interest rate
 
1.35-1.59%
Expected dividend yield
 
0%
Expected life
 
5 - 5.5 Years
Expected volatility
 
75.53-76.21%
  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The Company has excluded the following outstanding warrants and options from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented:
 
        
 
As of December 31,
Common Equivalent Securities
2016
 
2015
Warrants
2,148,741

 
2,222,155

Options
233,367

 
343,643

Total
2,382,108

 
2,565,798